
Guggenheim analyst Debjit Chattopadhyay lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $65 from $80 and keeps a Buy rating on the shares. Cutting the FY26 outlook by
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| IONS | Ionis Pharmaceuticals | 26.96 | -47.54 | -63.81% |
| Name | Price | % Change | |
|---|---|---|---|
| $26.96 | -63.81% |

Guggenheim analyst Debjit Chattopadhyay lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $65 from $80 and keeps a Buy rating on the shares. Cutting the FY26 outlook by

Ionis Pharmaceuticals (IONS) announced that the European Commission, or EC, has approved Tryngolza as an adjunct to diet, in combination with other lipid-lowering therapies, for the treatment of adult patients

Ionis Pharmaceuticals Inc. (($IONS)) has held its Q3 earnings call. Read on for the main highlights of the call. Ionis Pharmaceuticals’ earnings call carried a broadly positive tone, led by

Ionis Pharmaceuticals (IONS) announced new long-term data for DAWNZERA, the first and only RNA-targeted medicine for hereditary angioedema, to be presented at the 2026 American College of Allergy, Asthma &

Barclays lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $70 from $85 and keeps an Overweight rating on the shares. The firm updated the company’s model post the

Piper Sandler lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $60 from $87 and keeps an Overweight rating on the shares. Published first on TheFly – the ultimate

Wells Fargo analyst Yanan Zhu lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $80 from $95 and keeps an Overweight rating on the shares. Tryngolza launch was more

H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $70 from $100 and keeps a Buy rating on the shares post the Q3 report.

Goldman Sachs lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $41 from $58 and keeps a Neutral rating on the shares. Ionis faces near-term specialty cardiovascular launch headwinds

BofA lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $63 from $91 and keeps a Buy rating on the shares. While it is “not a surprise” that Ionis
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Reiterated | Nov 16, 2026 | ||||
| buy | Reiterated | Nov 11, 2026 | ||||
| buy | Reiterated | Nov 10, 2026 | ||||
| buy | Reiterated | Nov 10, 2026 | ||||
| buy | Assigned | Nov 10, 2026 | ||||
| buy | Reiterated | Nov 10, 2026 | ||||
| buy | Reiterated | Nov 10, 2026 | ||||
| buy | Assigned | Nov 10, 2026 | ||||
| buy | Reiterated | Nov 9, 2026 | ||||
| buy | Reiterated | Nov 9, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Feb 24, 2027TBA | $4.49B | $-1.36 | $176.97M | 1.53 | -8.07 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.